Follow NaDeNo’s progress as we advance PACAB-002 toward clinical investigation, expand our nanoparticle platform and build collaborations across oncology, nanomedicine and drug delivery.
NaDeNo’s lead candidate PACAB-002 is granted Orphan Drug Designation
NaDeNo selected for EIC Accelerator funding
NaDeNo seeks funding ahead of clinical entry
NaDeNo Presents at GoCo Investor Day
NaDeNo joins AstraZeneca’s BioVentureHub
NaDeNo Welcomes Dr. Jens Bjørheim as Chief Medical Officer
NaDeNo Tops PHOENIX OITB Rankings: A Big Leap Toward Clinical Trials
NaDeNo welcomes Gudrun Trøite as Head of Operations
Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
